- ►diabetesmidt.dk [PDF] J Lindström, P Ilanne-Parikka, M Peltonen, S … - The Lancet, 2006 - Elsevier During the total follow-up, the incidence of type 2 diabetes was 4·3 and 7·4
per 100 person-years in the intervention and control group, respectively
(log-rank test p=0·0001), indicating 43% reduction in relative risk. The ... Cited by 236 - Related articles - BL Direct - All 11 versions
- ►annals.org [PDF] DM Eddy, L Schlessinger, R Kahn - Annals of Internal Medicine, 2005 - Am Coll Physicians Data Sources: Published basic and epidemiologic studies, clin- ical trials, and
Kaiser Permanente administrative data. Target Population: Adults at high risk
for diabetes (body mass index >24 kg/m2, fasting plasma glucose level of ... Cited by 122 - Related articles - BL Direct - All 7 versions
- ►ksu.edu.sa [PDF] JP Bantle, RJ Wylie, AL Albright, CM …, 2006 - repository.ksu.edu.sa M edical nutrition therapy (MNT) is important in preventing diabetes, managing
existing diabetes, and preventing, or at least slowing, the rate of development
of diabetes complications. It is, therefore, important at all levels of di- ... Cited by 64 - Related articles - View as HTML - All 3 versions
- ►nih.gov EHB Lin, W Katon, C Rutter, GE Simon, EJ … - The Annals of Family Medicine, 2006 - Annals Family Med METHODS A total of 329 patients in 9 primary care clinics were randomized to an
evidence-based collaborative depression treatment (pharmacotherapy,
problem-solving treatment, or both in combination) or usual primary care ( ... Cited by 49 - Related articles - BL Direct - All 10 versions
- ►nih.gov RE Ratner, DPPR Group - Endocrine Practice, 2006 - AACE The Diabetes Prevention Program (DPP) was a National Institutes of
Health-sponsored, multicentered, clinical trial conducted in 27 clinical centers
throughout the United States, with recruitment initiated in July 1996. The ... Cited by 51 - Related articles - BL Direct - All 3 versions
PC Deedwania, VA Fonseca - The American journal of medicine, 2005 - Elsevier As the prevalence of diabetes continues to increase worldwide, diabetes-related
macrovascular morbidity and mortality are becoming major health care problems.
Epidemiologic evidence suggests this relationship begins early in the ... Cited by 48 - Related articles - All 14 versions
EN Liberopoulos, S Tsouli, DP Mikhailidis, MS … - Current Drug Targets, 2006 - ingentaconnect.com 1Department of Clinical Biochemistry (Vascular Disease Prevention clinics),
Royal Free Hospital University College School of Medicine (University of
London), London, UK and 2Department of Internal Medicine, School of ... Cited by 48 - Related articles - BL Direct - All 2 versions
JA Cramer, A Benedict, N Muszbek, A … - International Journal of Clinical Practice, 2008 - pubmedcentral.nih.gov Disclosures The data in this paper were presented in part at the 16th European
Meeting on Hypertension, 12–15 June 2006, Madrid, Spain and ISPOR 9th Annual
European Congress, 28–31 October 2006, Copenhagen, Denmark. Development ... Cited by 29 - Related articles - BL Direct - All 5 versions
J Tuomilehto, N Wareham - The Lancet, 2006 - Elsevier Rosiglitazone has been approved as a drug that lowers plasma glucose
concentrations and is licensed for use in diabetes. In DREAM, rosiglitazone
lowered the 2-h plasma glucose concentration by 1·6 mmol/L in people with ... Cited by 23 - Related articles - All 8 versions
RT Ackermann, DG Marrero - The Diabetes Educator, 2007 - tde.sagepub.com The Diabetes Prevention Program (DPP) demonstrated that a structured diet and
physical activity intervention that achieves and maintains modest weight loss
for overweight adults with impaired glucose tolerance can significantly ... Cited by 23 - Related articles - BL Direct - All 3 versions
